Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a $15 price target on the company's stock.

January 16, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Recursion Pharmaceuticals and maintains a $15 price target.
The reiteration of a Buy rating by a reputable analyst like Gil Blum from Needham is a positive signal for investors, suggesting confidence in the company's future performance. The maintained price target of $15 indicates that the analyst believes the stock has the potential to reach or exceed this value in the short term, which could influence investor sentiment and drive the stock price upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100